Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
309.03
-1.27 (-0.41%)
At close: May 29, 2026, 4:00 PM EDT
305.00
-4.03 (-1.30%)
After-hours: May 29, 2026, 7:59 PM EDT
Krystal Biotech Revenue
Krystal Biotech had revenue of $116.36M in the quarter ending March 31, 2026, with 31.95% growth. This brings the company's revenue in the last twelve months to $417.30M, up 25.15% year-over-year. In the year 2025, Krystal Biotech had annual revenue of $389.13M with 33.94% growth.
Revenue (ttm)
$417.30M
Revenue Growth
+25.15%
P/S Ratio
21.83
Revenue / Employee
$1,414,590
Employees
295
Market Cap
9.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 389.13M | 98.62M | 33.94% |
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Halozyme Therapeutics | 1.51B |
| Bio-Techne | 1.21B |
| Corcept Therapeutics | 769.10M |
| Arrowhead Pharmaceuticals | 622.01M |
| ImmunityBio | 140.98M |
| Cytokinetics | 105.82M |
| Praxis Precision Medicines | 7.46M |
KRYS News
- 10 days ago - Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - GlobeNewsWire
- 11 days ago - Krystal Biotech Slides: Corporate presentation - Filings
- 13 days ago - Krystal Biotech announces UK MHRA approval of Vyjuvek - TheFly
- 13 days ago - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 16 days ago - Krystal Biotech Transcript: AGM 2026 - Transcripts
- 16 days ago - U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa - TheFly
- 18 days ago - Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Krystal Biotech to Present at BofA Securities 2026 Health Care Conference - GlobeNewsWire